AP NEWS

Fanconi Anemia: H1 2018 Pipeline Review Covering Abeona Therapeutics, Genethon and Novartis - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Fanconi Anemia - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Fanconi Anemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fanconi Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.

Companies Mentioned

Abeona Therapeutics Inc Genethon SA Novartis AG

Key Topics Covered

Introduction Report Coverage Fanconi Anemia - Overview Fanconi Anemia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Fanconi Anemia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Fanconi Anemia - Companies Involved in Therapeutics Development Abeona Therapeutics Inc Genethon SA Novartis AG Fanconi Anemia - Drug Profiles ABO-301 - Drug Profile Product Description Mechanism Of Action R&D Progress eltrombopag olamine - Drug Profile Product Description Mechanism Of Action R&D Progress EXG-34217 - Drug Profile Product Description Mechanism Of Action R&D Progress Fancalen - Drug Profile Product Description Mechanism Of Action R&D Progress JP4-039 - Drug Profile Product Description Mechanism Of Action R&D Progress RPL-101 - Drug Profile Product Description Mechanism Of Action R&D Progress RPL-102 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Fanconi Anemia - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy 1 for Fanconi Anemia - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy to Activate FANC-A for Fanconi Anemia - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy to Activate FANCA for Fanconi Anemia - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy to Activate FANCA Protein for Fanconi Anemia - Drug Profile Product Description Mechanism Of Action R&D Progress Fanconi Anemia - Dormant Projects Fanconi Anemia - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/9vq533/fanconi_anemia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006507/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 02:06 PM/DISC: 06/05/2018 02:06 PM

http://www.businesswire.com/news/home/20180605006507/en

AP RADIO
Update hourly